For the Inventor, By the Inventor

Enter inventor name

South San Francisco, CA, United States of America

Rohan V Mendonca

USPTO Granted Patents = 15 (Patent Applications = 13)

EPO Patents = 10 (Patent Applications = 9)

Average Co-Inventor Count = 11.7

ph-index = 3

Forward Citations = 55(Granted Patents)

Location History:

Millbrae, CA (US) (2003)
South San Francisco, CA (US) (2003 - 2023)
Pleasanton, CA (US) (2013 - 2023)

Company Filing History:

13 out of 3,222

Genentech, Inc.

Axys Pharmaceuticals, Inc.

Newlink Genetics Corporation

4. 1 out of 4,770

Merck + Co., Inc.

where one patent can have more than one assignee

Years Active: 2003-2025

Loading Chart...

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12473301 - Isoquinoline compounds for the treatment of cancer (2025-11-18),

2. 12378249 - Isoquinoline compounds and uses thereof (2025-08-05),

3. 12297210 - Naphthyridine compounds and uses thereof (2025-05-13),

4. 11612606 - 8-aminoisoquinoline compounds and uses thereof (2023-03-28),

5. 11603373 - TDO2 and IDO1 inhibitors (2023-03-14),

6. 11566003 - Isoquinolines as inhibitors of HPK1 (2023-01-31),

7. 11034692 - Naphthyridines as inhibitors of HPK1 (2021-06-15),

8. 10800780 - TDO2 Inhibitors (2020-10-13),

9. 10407424 - Naphthyridines as inhibitors of HPK1 (2019-09-10),

10. 9604984 - 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof (2017-03-28),

11. 9346815 - 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof (2016-05-24),

12. 8999998 - Pyrazolopyrimidine JAK inhibitor compounds and methods (2015-04-07),

13. 8461328 - Tricyclic heterocyclic compounds, compositions and methods of use thereof (2013-06-11),

14. 6525036 - Compounds and compositions as protease inhibitors (2003-02-25),

15. 6506733 - Compounds and compositions as protease inhibitors (2003-01-14),

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…